

August 30, 2016

MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results for first half-year 2016:

Net profit EUR 19.88 million (46 Cent per share) in first half-year, profit increase in second quarter of 29% compared to first quarter 2016, equity EUR 153.49 million (3.58 EUR per share)

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the first half-year 2016.

In the first half-year 2016 the preliminary IFRS Group net profit amounted to EUR 19.88 million.

The investments listed on Frankfurt Stock Exchange, HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG performed successfully in the first half-year 2016.

HAEMATO achieved in the first half-year sales growth and profit (EBIT) growth of 40%. M1 Kliniken AG enlarged the clinic in Berlin to six operating rooms and 34 patient beds. After further openings M1 is now active with twelve M1-outpatient service centres throughout Germany.

Sales of EUR 18.5 million in the first half-year shall be outperformed in the second half-year. Both companies, HAEMATO and M1, paid a dividend of 30 Cent per share to their shareholders in June 2016.

CR Capital Real Estate AG reported on its general annual meeting on August 18th about progress in the project developments.

MPH paid a dividend of 12 Cent per share in June 2016.

„The net income of EUR 11.19 million in the first quarter outperformed the net income of EUR 8.69 million achieved in the first quarter by 28.7%

We saw in the second quarter a successful development in the effort to make a contribution in keeping healthcare affordable and we are confident for the further income development in 2016“, say Patrick Brenske und Dr. Christian Pahl, Members of the Management Board of MPH.

Kontakt:

MPH Mittelständische Pharma Holding AG
Susanne Seger
Grünauer Straße 5
D-12557 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 69

E-Mail: ir@mph-ag.de
Web: www.mph-ag.de

August 30, 2016

About MPH Mittelständische Pharma Holding AG:

MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments. But also beyond the healthcare market MPH makes use of potentials of high growth areas.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 42,813,842

Listed shares: ordinary shares

ISIN: DE000A0L1H32

WKN: A0L1H3

Stock symbol: 93M

Contact:

Susanne Seger

MPH Mittelständische Pharma Holding AG

Grünauer Straße 5

D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669

E-Mail: ir@mph-ag.de Web: www.mph-ag.de

Kontakt:

MPH Mittelständische Pharma Holding AG

Susanne Seger

Grünauer Straße 5

D-12557 Berlin

Tel.: +49 (0) 30 897 30 86 60

Fax: +49 (0) 30 897 30 86 69

E-Mail: ir@mph-ag.de

Web: www.mph-ag.de